PHARVARIS NV (PHVS:NASDAQ)
$34.93 0.32 (0.9246%)
Analysed PHARVARIS NV (PHVS:NASDAQ) News Sources
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
29-05-2026
yahoo.com
Pharvaris Announces Annual General Meeting of Shareholders
11-06-2026
yahoo.com
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
15-06-2026
yahoo.com
Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development
06-07-2026
yahoo.com
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy
15-07-2026
yahoo.com
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
22-07-2026
yahoo.com
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet
31-07-2026
yahoo.com
Pharvaris (PHVS) Stock May Be Pricey After A 103% Five Year Run
03-08-2026
yahoo.com
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
06-08-2026
yahoo.com
Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says
13-08-2026
yahoo.com
What is the current price of PHARVARIS NV (PHVS:NASDAQ)?
The current price of PHARVARIS NV (PHVS:NASDAQ) is $34.93.
PHARVARIS NV (PHVS:NASDAQ) absolute price change since previous trading day?
The absolute price change of PHARVARIS NV (PHVS:NASDAQ) since the previous trading day is $0.32.
PHARVARIS NV (PHVS:NASDAQ) percentage price change since previous trading day?
The percentage price change of PHARVARIS NV (PHVS:NASDAQ) since the previous trading day is 0.9246%.
What is the most recent average sentiment score for PHARVARIS NV (PHVS:NASDAQ)?
The most recent average sentiment score for PHARVARIS NV (PHVS:NASDAQ) is 60 out of 100.
What is the most recent average sentiment for PHARVARIS NV (PHVS:NASDAQ)?
The most recent sentiment for PHARVARIS NV (PHVS:NASDAQ) is .
SEC-8K** Filing Available For PHARVARIS NV (PHVS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.